Clinical trial to determine whether nipocalimab can prevent FNAIT
A clinical trial sponsored by Johnson & Johnson will seek to determine whether nipocalimab prevents or delays FNAIT in at-risk pregnancies.
A clinical trial sponsored by Johnson & Johnson will seek to determine whether nipocalimab prevents or delays FNAIT in at-risk pregnancies.
A recent study found that severe maternal thrombocytopenia may increase the risk of neonatal thrombocytopenia.
A study by Rallybio is currently underway to determine whether the risk of FNAIT differs by race or ethnicity.
Although rare, thrombocytopenia is an adverse effect that may be associated with intravenous immunoglobulin therapy, a recent study found
Recent strategies have emerged to improve the quality and supply of platelets for transfusions, a key treatment for patients with FNAIT.
A recent study found that children with FNAIT may be at an elevated risk of developing autism later in childhood, regardless of ICH status.
A high frequency ultrasound can reveal a buildup of fluid surrounding the brains of infants a recent study found.
A review describes advancements in stem cell therapy, artificial womb technology and telehealth, which may improve care for FNAIT.
A recent report described three cases of infants with thrombocytopenia who were successfully treated with romiplostim.
Fetal maternal hemorrhage, a potential cause of FNAIT, must treated as soon as possible, a recent case report and literature review found.